**SUPPLEMENTARY TABLE 2** Complete response, complete control, and total response during delayed, overall, and acute phases of CINV among female patients (cisplatin stratum, mITT population)

<table>
<thead>
<tr>
<th>Response, CINV phase</th>
<th>Arm, n (%)</th>
<th>Treatment difference (APF530-ondansetron) (95% CI), %</th>
<th>P value&lt;sup&gt;a&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>APF530 500 mg SC (n = 51)</td>
<td>Ondansetron 0.15 mg/kg IV (n = 62)</td>
<td></td>
</tr>
<tr>
<td>Complete response</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Delayed</td>
<td>32 (62.7)</td>
<td>31 (50.0)</td>
<td>12.7 (-5.4, 30.9)</td>
</tr>
<tr>
<td>Overall</td>
<td>31 (60.8)</td>
<td>30 (48.4)</td>
<td>12.4 (-5.9, 30.7)</td>
</tr>
<tr>
<td>Acute</td>
<td>42 (82.4)</td>
<td>45 (72.6)</td>
<td>9.8 (-5.5, 25.0)</td>
</tr>
<tr>
<td>Complete control</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Delayed</td>
<td>30 (58.8)</td>
<td>30 (48.4)</td>
<td>10.4 (-7.9, 28.8)</td>
</tr>
<tr>
<td>Overall</td>
<td>29 (56.9)</td>
<td>29 (46.8)</td>
<td>10.1 (-8.3, 28.5)</td>
</tr>
<tr>
<td>Acute</td>
<td>42 (82.4)</td>
<td>43 (69.4)</td>
<td>13.0 (-2.5, 28.5)</td>
</tr>
<tr>
<td>Total response</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Delayed</td>
<td>27 (52.9)</td>
<td>24 (38.7)</td>
<td>14.2 (-4.1, 32.5)</td>
</tr>
<tr>
<td>Overall</td>
<td>27 (52.9)</td>
<td>24 (38.7)</td>
<td>14.2 (-4.1, 32.5)</td>
</tr>
<tr>
<td>Acute</td>
<td>41 (80.4)</td>
<td>43 (69.4)</td>
<td>11.0 (-4.8, 26.9)</td>
</tr>
</tbody>
</table>

CI, confidence interval; CINV, chemotherapy-induced nausea and vomiting; IV, intravenously; mITT, modified intent-to-treat; SC, subcutaneously

<sup>a</sup>P values are based on the chi-square test.